Holen Sie sich die Stockscreener-App
19.16
4.70%
0.86
Vorhandelsmarkt:
19.19
0.03
+0.16%
Schlusskurs vom Vortag:
$18.30
Offen:
$18.29
24-Stunden-Volumen:
2.36M
Relative Volume:
0.60
Marktkapitalisierung:
$14.23B
Einnahmen:
$220.00K
Nettoeinkommen (Verlust:
$-746.08M
KGV:
-19.02
EPS:
-1.0074
Netto-Cashflow:
$-211.81M
1W Leistung:
+9.55%
1M Leistung:
-10.26%
6M Leistung:
-20.03%
1J Leistung:
-11.99%
1-Tages-Spanne:
$18.16
$19.20
1-Wochen-Bereich:
$17.37
$19.20
52-Wochen-Spanne:
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Vergleichen Sie SMMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
19.16 | 13.62B | 220.00K | -746.08M | -211.81M | -1.0074 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.22 | 106.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
674.55 | 68.81B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.95 | 58.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
889.64 | 53.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.69 | 40.93B | 447.02M | -1.18B | -906.14M | -6.1812 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Eingeleitet | Barclays | Underweight |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Neutral |
| 2025-07-01 | Eingeleitet | UBS | Buy |
| 2025-06-11 | Eingeleitet | Leerink Partners | Underperform |
| 2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | Goldman | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-07 | Eingeleitet | Citigroup | Buy |
| 2024-03-26 | Eingeleitet | Stifel | Buy |
| 2018-06-28 | Herabstufung | Janney | Buy → Neutral |
| 2018-05-02 | Eingeleitet | Janney | Buy |
| 2018-04-12 | Bestätigt | Needham | Buy |
| 2018-02-13 | Eingeleitet | BTIG Research | Buy |
| 2018-01-04 | Eingeleitet | SunTrust | Buy |
| 2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-05 | Bestätigt | Needham | Buy |
| 2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-30 | Eingeleitet | Needham | Buy |
| 2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
Has Summit Therapeutics Inc. found a price floor2025 Trading Recap & Long Hold Capital Preservation Tips - newser.com
What MACD and RSI say about Summit Therapeutics Inc.July 2025 Intraday Action & Community Trade Idea Sharing - newser.com
Analyzing Summit Therapeutics Inc. with risk reward ratio chartsWeekly Trend Summary & Community Trade Idea Sharing Platform - newser.com
Is Summit Therapeutics Inc. building a consolidation baseJuly 2025 Technicals & Expert Curated Trade Setup Alerts - newser.com
Can Summit Therapeutics Inc. hit a new high this monthInsider Selling & Weekly Return Optimization Plans - newser.com
Summit Therapeutics (SMMT) Reports Positive Results from the Phase III HARMONi Trial - Yahoo Finance
Responsive Playbooks and the SMMT Inflection - news.stocktradersdaily.com
Summit and Akeso ivonescimab’s shows significant OS benefit - The Pharma Letter
Insiders Are Buying These 3 Stocks Hand Over Fist - AOL.com
What institutional flow reveals about Summit Therapeutics Inc.2025 Market Outlook & Weekly High Momentum Picks - newser.com
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China - Placera.se
Summit Therapeutics Says Ivonescimab, Chemotherapy Combination Shows Benefit in Treating Lung Cancer - MarketScreener
Summit Therapeutics Reports Positive Phase III Trial Results - TipRanks
Summit Therapeutics Inc Reports Positive Phase III Trial Results - TradingView
[8-K] Summit Therapeutics Inc. Reports Material Event | SMMT SEC FilingForm 8-K - Stock Titan
Summit (NASDAQ: SMMT): ivonescimab combo OS 16.8 vs 14.1 mo in EGFRm NSCLC - Stock Titan
Should you hold or exit Summit Therapeutics Inc. nowEarnings Overview Summary & Advanced Technical Signal Analysis - newser.com
Is Summit Therapeutics Inc. showing signs of accumulationJuly 2025 Price Swings & Weekly Hot Stock Watchlists - newser.com
Will Summit Therapeutics Inc. stock outperform growth indexesSwing Trade & Verified Short-Term Trading Plans - fcp.pa.gov.br
Applying sector rotation models to Summit Therapeutics Inc.Weekly Profit Analysis & AI Powered Market Entry Strategies - newser.com
Transforming Lung Cancer Care Through Targeted Science and Patient-First InnovationSummit Therapeutics - Oncodaily
Summit Therapeutics to Present at Upcoming Investor ConferencesNovember 4, 2025 - BioSpace
Is Summit Therapeutics Inc. stock reversal real or fakeShare Buyback & Daily Oversold Bounce Ideas - newser.com
Summit Therapeutics Inc.Common Stock (Nasdaq:SMMT) Stock Quote - Markets Financial Content
Summit Therapeutics Earnings Notes - Trefis
Summit Therapeutics (SMMT) Is Down 6.4% After $513M Shelf Filing and Ivonescimab Clinical Updates—Has The Bull Case Changed? - Yahoo Finance
News impact scoring models applied to Summit Therapeutics Inc.Trade Signal Summary & Daily Technical Forecast Reports - newser.com
A Look at Summit Therapeutics (SMMT) Valuation Following Positive HARMONi Trial Results and Regulatory Progress - Yahoo Finance
1 Monster Stock in the Making to Buy and Hold - AOL.com
Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors - MSN
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Insiders Are Snapping Up These 2 Stocks — and Analysts Like What They See - Yahoo Finance
Summit (NASDAQ: SMMT) at SITC 2025: HARMONi-A; first Phase III OS benefit for ivonescimab - Stock Titan
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):